Tesaglitazar [CAS 251565-85-2]

Tesaglitazar is a dual-target PPARα/γ agonist with an EC50 of 13.4 μM for rat PPARα and 3.6 μM for human PPARα. Tesaglitazar affects lipid and glucose metabolism by activating PPARα and PPARγ receptors, and has the potential to improve blood sugar and relieve pain. Tesaglitazar can be used to induce in vivo tumor models and can be used in the study of type 2 diabetes, dyslipidemia, and neuropathic pain[1][2][3].

[251565-85-2]

C20H24O7S

408.47

O=C(O)[C@@H](OCC)CC1=CC=C(OCCC2=CC=C(OS(=O)(C)=O)C=C2)C=C1

PPAR

99.08

DMSO : 200 mg/mL (ultrasonic; warming; heat to 60°C)

-20°C (Powder, sealed storage, away from moisture)

Blue Ice

H302

H302